|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
EP0092918B1
(en)
|
1982-04-22 |
1988-10-19 |
Imperial Chemical Industries Plc |
Continuous release formulations
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
AU6430190A
(en)
|
1989-10-10 |
1991-05-16 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2071867A1
(en)
|
1989-11-06 |
1991-05-07 |
Edith Mathiowitz |
Method for producing protein microspheres
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
WO1992010591A1
(en)
|
1990-12-14 |
1992-06-25 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
EP0571613B1
(en)
|
1991-12-13 |
2003-09-17 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
|
ES2156149T3
(es)
|
1992-12-04 |
2001-06-16 |
Medical Res Council |
Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
HUT76369A
(en)
|
1994-07-29 |
1997-08-28 |
Smithkline Beecham Corp |
Novel soluble protein compounds
|
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
|
ATE252894T1
(de)
|
1995-01-05 |
2003-11-15 |
Univ Michigan |
Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
|
|
EP1658772A3
(en)
|
1995-01-17 |
2007-01-17 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
WO1997007788A2
(en)
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics, Inc. |
Composition for sustained release of an agent
|
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
DK2093286T3
(da)
|
2001-10-01 |
2013-05-13 |
Dyax Corp |
Flerkædede, eukaryote displayvektorer og anvendelser deraf
|
|
US20040005709A1
(en)
|
2001-10-24 |
2004-01-08 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
Hybridization control of sequence variation
|
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US8603930B2
(en)
|
2005-10-07 |
2013-12-10 |
Sulzer Metco (Us), Inc. |
High-purity fused and crushed zirconia alloy powder and method of producing same
|
|
US20090075378A1
(en)
|
2007-02-20 |
2009-03-19 |
Anaptysbio, Inc. |
Somatic hypermutation systems
|
|
ES2582340T3
(es)
|
2008-01-15 |
2016-09-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Métodos para manipular fagocitosis mediada por CD47
|
|
EP2111869A1
(en)
|
2008-04-23 |
2009-10-28 |
Stichting Sanquin Bloedvoorziening |
Compositions and methods to enhance the immune system
|
|
CA2771336C
(en)
|
2009-09-15 |
2019-11-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synergistic anti-cd47 therapy for hematologic cancers
|
|
RU2608644C2
(ru)
*
|
2010-11-03 |
2017-01-23 |
арДЖЕН-ИКС Н.В. |
Антитела против белка рецептора с-мет
|
|
US20140271683A1
(en)
|
2010-12-21 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
|
|
US9574002B2
(en)
*
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
WO2013056352A1
(en)
|
2011-10-19 |
2013-04-25 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
|
EP2953633B1
(en)
|
2013-02-05 |
2017-10-04 |
The Board of Trustees of the Leland Stanford Junior University |
Cd47 targeted therapies for the treatment of infectious disease
|
|
CN112245586A
(zh)
|
2013-03-15 |
2021-01-22 |
小利兰·斯坦福大学托管委员会 |
用于实现治疗有效剂量的抗cd47剂的方法
|
|
JP6843611B2
(ja)
|
2013-04-29 |
2021-03-17 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
免疫を強化する抗ｃｄ４７因子の使用
|
|
US9945870B2
(en)
|
2013-05-17 |
2018-04-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for determining responsiveness to an anti-CD47 agent
|
|
US9667770B2
(en)
|
2013-07-17 |
2017-05-30 |
Flypsi, Inc. |
Telephone network system and method
|
|
EP3046627B1
(en)
|
2013-09-18 |
2019-10-23 |
The Board of Trustees of the Leland Stanford Junior University |
Modulation of efferocytosis pathways for treatment of atherosclerotic disease
|
|
CN106456748A
(zh)
|
2014-01-08 |
2017-02-22 |
小利兰·斯坦福大学托管委员会 |
小细胞肺癌的靶向疗法
|
|
CN106456749B
(zh)
*
|
2014-03-11 |
2021-03-30 |
小利兰·斯坦福大学托管委员会 |
抗SIRPα抗体和双特异性巨噬细胞增强型抗体
|
|
WO2016022971A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Sirp alpha-antibody fusion proteins
|
|
EP4257145B1
(en)
|
2014-08-26 |
2025-06-25 |
The Board of Trustees of the Leland Stanford Junior University |
Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
|
|
US10822411B2
(en)
|
2014-09-15 |
2020-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
|
WO2016065245A1
(en)
|
2014-10-24 |
2016-04-28 |
Incept, Llc |
Extra luminal scaffold
|
|
CA2959821C
(en)
|
2014-10-24 |
2024-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
|
|
GB201503387D0
(en)
*
|
2015-02-27 |
2015-04-15 |
ALERE TECHNOLOGIES GmbH |
Anti-carbapenem antibodies and uses thereof
|
|
ES2761861T3
(es)
|
2015-01-21 |
2020-05-21 |
Univ Leland Stanford Junior |
Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
|
|
WO2016138306A1
(en)
|
2015-02-27 |
2016-09-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Combination therapy for treatment of coronary artery disease
|
|
EP3265486A4
(en)
*
|
2015-03-06 |
2018-11-14 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
|
SI3280441T1
(sl)
*
|
2015-04-07 |
2022-01-31 |
Alector Llc |
Protitelesa anti-sortilin in metoda njihove uporabe
|
|
WO2016205042A1
(en)
|
2015-06-16 |
2016-12-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRPα AGONIST ANTIBODY
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
AU2016304794B2
(en)
|
2015-08-07 |
2021-07-15 |
ALX Oncology Inc. |
Constructs having a SIRP-alpha domain or variant thereof
|
|
AU2016310348B2
(en)
|
2015-08-26 |
2023-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
|
|
WO2017068164A1
(en)
|
2015-10-21 |
2017-04-27 |
Ose Immunotherapeutics |
Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
|
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3165536A1
(en)
|
2015-11-09 |
2017-05-10 |
Ludwig-Maximilians-Universität München |
Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
|
|
US10946042B2
(en)
|
2015-12-01 |
2021-03-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for selective phagocytosis of human cancer cells
|
|
JP7036729B2
(ja)
|
2016-01-08 |
2022-03-15 |
クリング・バイオセラピューティックス・べー・フェー |
治療用抗ｃｄ９抗体
|
|
US20170210803A1
(en)
|
2016-01-21 |
2017-07-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of cancer with combinations of immunoregulatory agents
|
|
WO2017152132A1
(en)
|
2016-03-04 |
2017-09-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of identifying and treating immune checkpoint inhibitor-responsive neoplasms
|
|
WO2017160717A2
(en)
|
2016-03-15 |
2017-09-21 |
Memorial Sloan Kettering Cancer Center |
Method of treating diseases using kinase modulators
|
|
WO2017180519A1
(en)
|
2016-04-10 |
2017-10-19 |
George State University Research Foundation, Inc. |
Methods for treating cancer and inhibiting graft rejection
|
|
WO2017180546A1
(en)
|
2016-04-11 |
2017-10-19 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating and preventing lung disease
|
|
IL262251B2
(en)
|
2016-04-14 |
2023-09-01 |
Ose Immunotherapeutics |
New anti-syrap antibodies and their medical applications
|
|
BR112018070823A2
(pt)
*
|
2016-04-14 |
2019-02-05 |
Ose Immunotherapeutics |
anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
|
|
KR102505253B1
(ko)
|
2016-04-15 |
2023-03-02 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
|
|
WO2017184553A1
(en)
|
2016-04-18 |
2017-10-26 |
Baylor College Of Medicine |
Cancer gene therapy targeting cd47
|
|
JP7160683B2
(ja)
|
2016-04-29 |
2022-10-25 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
術後癒着の予防及び治療のための方法及び組成物
|
|
US20190135921A1
(en)
|
2016-05-19 |
2019-05-09 |
Adaerata, Limited Partnership |
Methods of preventing or treating slamf7 positive and slamf7 negative cancers
|
|
CN109475627B
(zh)
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
抗体混合物
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018005775A1
(en)
|
2016-06-29 |
2018-01-04 |
Memorial Sloan-Kettering Cancer Center |
Cd47 blockade enhances therapeutic activity of antibodies to low density cancer epitopes
|
|
WO2018008470A1
(ja)
|
2016-07-05 |
2018-01-11 |
国立大学法人神戸大学 |
抗腫瘍剤
|
|
CN109862910A
(zh)
|
2016-08-03 |
2019-06-07 |
小利兰·斯坦福大学托管委员会 |
破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
|
|
WO2018037091A1
(en)
|
2016-08-24 |
2018-03-01 |
Hi-Stem Ggmbh |
Methods for the identification and isolation of hematopoietic stem and progenitor cells
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
AU2017332960B2
(en)
*
|
2016-10-20 |
2019-09-12 |
I-Mab Biopharma Us Limited |
Novel CD47 monoclonal antibodies and uses thereof
|
|
CA3042581A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
AU2017371070B2
(en)
*
|
2016-12-09 |
2025-01-02 |
Alector Llc |
Anti-SIRP-alpha antibodies and methods of use thereof
|
|
JP7179743B2
(ja)
|
2017-02-17 |
2022-11-29 |
オーエスイー・イミュノセラピューティクス |
抗ＳＩＲＰｇ抗体の新規の使用
|
|
WO2018160739A1
(en)
|
2017-02-28 |
2018-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antifibrotic activity of cd47 blockade
|
|
WO2018165015A1
(en)
|
2017-03-09 |
2018-09-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of pediatric brain tumors with targeting of cd47 pathway
|
|
WO2018184003A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
|
|
KR102702926B1
(ko)
|
2017-04-13 |
2024-09-06 |
사이로파 비.브이. |
항-sirp 알파 항체
|
|
CN118271443A
(zh)
|
2017-05-16 |
2024-07-02 |
拜奥迪斯私人有限公司 |
抗SIRPα抗体
|
|
US11740242B2
(en)
|
2017-07-14 |
2023-08-29 |
Dana-Farber Cancer Institute, Inc. |
Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
|
|
WO2019014663A1
(en)
|
2017-07-14 |
2019-01-17 |
Dana-Farber Cancer Institute, Inc. |
MODULATION OF BIOMARKERS TO INCREASE ANTI-TUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF CANCER IMMUNOTHERAPY
|
|
WO2019014664A1
(en)
|
2017-07-14 |
2019-01-17 |
Dana-Farber Cancer Institute, Inc. |
MODULATION OF BIOMARKERS TO INCREASE ANTITUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF ANTICANCER IMMUNOTHERAPY
|
|
EP3654976A1
(en)
|
2017-07-21 |
2020-05-27 |
Varian Medical Systems, Inc. |
Methods of use of ultra-high dose rate radiation and therapeutic agents
|
|
EP3747438A1
(en)
|
2017-07-24 |
2020-12-09 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction
|
|
BR112020001653A2
(pt)
|
2017-07-26 |
2020-07-21 |
Forty Seven, Inc. |
anticorpos anti-sirp-alfa e métodos relacionados
|
|
EP3694881A1
(en)
|
2017-10-13 |
2020-08-19 |
OSE Immunotherapeutics |
Modified anti-sirpa antibodies and uses thereof
|
|
US11771764B2
(en)
|
2017-11-06 |
2023-10-03 |
Pfizer Inc. |
CD47 blockade with radiation therapy
|
|
WO2019090355A1
(en)
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
US12053523B2
(en)
|
2017-12-13 |
2024-08-06 |
North Carolina State University |
Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
|
|
GB201800649D0
(en)
|
2018-01-16 |
2018-02-28 |
Argenx Bvba |
CD70 Combination Therapy
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
CN108484774B
(zh)
*
|
2018-03-09 |
2021-11-05 |
上海高菲生物科技有限公司 |
一种SIRPα融合蛋白及其制备方法和用途
|